Literature DB >> 10717351

Rapid antibody response to influenza vaccination in "at risk" groups.

R Lambkin1, J S Oxford, L Biao, A Al-Jabri, D Fleming.   

Abstract

Persons attending for routine influenza vaccination in an urban practice each provided three specimens of blood for evaluating their immunological response. 138 (67%) of the 206 persons were defined as "at risk" by reason of morbidity as given in the guidelines published by the Chief Medical Officer. The mean age was 67 yr and 65% were aged 65 yr or more. By day 7, 71% of 31 persons had protective H(1)N(1) titres, 61% H(3)N(2) and 42% B. These proportions were similar to those found at day 14 and at day 21 based on 159 persons. These findings suggest that an effective immune response is mounted within seven days of vaccination indicating that the vaccination of persons "at risk" is worthwhile even after an epidemic has established itself. This is not a reason to modify present policy of routine vaccination in early winter well before epidemics are likely to occur.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10717351     DOI: 10.1016/s0264-410x(99)00437-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Efficacy of the influenza vaccine in patients with malignant lymphoma.

Authors:  Joseph J Mazza; Steven H Yale; Jodi R Arrowood; Cory E Reynolds; Ingrid Glurich; Po-Huang Chyou; James G Linneman; Kurt D Reed
Journal:  Clin Med Res       Date:  2005-11

2.  Immunogenicity and safety of an inactivated trivalent split influenza virus vaccine in young children with recurrent wheezing.

Authors:  E Young Bae; Ui Yoon Choi; Hyo Jin Kwon; Dae Chul Jeong; Jung Woo Rhim; Sang Hyuk Ma; Kyung Il Lee; Jin Han Kang
Journal:  Clin Vaccine Immunol       Date:  2013-03-27

Review 3.  Lessons from 40 years' surveillance of influenza in England and Wales.

Authors:  D M Fleming; A J Elliot
Journal:  Epidemiol Infect       Date:  2007-11-30       Impact factor: 2.451

4.  Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities.

Authors:  Marie R Griffin; Arnold S Monto; Edward A Belongia; John J Treanor; Qingxia Chen; Jufu Chen; H Keipp Talbot; Suzanne E Ohmit; Laura A Coleman; Gerry Lofthus; Joshua G Petrie; Jennifer K Meece; Caroline Breese Hall; John V Williams; Paul Gargiullo; LaShondra Berman; David K Shay
Journal:  PLoS One       Date:  2011-08-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.